Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence
The recurrence of glioma is a difficult problem in clinical treatment. The molecular markers of primary tumors after resection cannot fully represent the characteristics of recurrent tumors. Here, abundant tumor DNA was detected in tumor in situ fluid (TISF). We report that TISF-derived tumor DNA (T...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.742037/full |
| id |
doaj-e15e187d8d9247cc898cae06f77afda2 |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Jinliang Yu Zhiyuan Sheng Zhiyuan Sheng Shuang Wu Shuang Wu Yushuai Gao Yushuai Gao Zhaoyue Yan Zhaoyue Yan Chaojie Bu Chaojie Bu Jianjun Gu Jianjun Gu Yage Bu Yage Bu Kaiyuan Deng Kaiyuan Deng Sensen Xu Sensen Xu Zhongcan Chen Zhongcan Chen Zhang Qianqian Zenmar Ajmal Juha Hernesniemi Juha Hernesniemi Meiyun Wang Meiyun Wang Gang Liu Tianxiao Li Tianxiao Li Xingyao Bu Xingyao Bu |
| spellingShingle |
Jinliang Yu Zhiyuan Sheng Zhiyuan Sheng Shuang Wu Shuang Wu Yushuai Gao Yushuai Gao Zhaoyue Yan Zhaoyue Yan Chaojie Bu Chaojie Bu Jianjun Gu Jianjun Gu Yage Bu Yage Bu Kaiyuan Deng Kaiyuan Deng Sensen Xu Sensen Xu Zhongcan Chen Zhongcan Chen Zhang Qianqian Zenmar Ajmal Juha Hernesniemi Juha Hernesniemi Meiyun Wang Meiyun Wang Gang Liu Tianxiao Li Tianxiao Li Xingyao Bu Xingyao Bu Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence Frontiers in Oncology precision medicine tumor in-situ fluid circulating tumor DNA spatiotemporal heterogeneity glioma progression |
| author_facet |
Jinliang Yu Zhiyuan Sheng Zhiyuan Sheng Shuang Wu Shuang Wu Yushuai Gao Yushuai Gao Zhaoyue Yan Zhaoyue Yan Chaojie Bu Chaojie Bu Jianjun Gu Jianjun Gu Yage Bu Yage Bu Kaiyuan Deng Kaiyuan Deng Sensen Xu Sensen Xu Zhongcan Chen Zhongcan Chen Zhang Qianqian Zenmar Ajmal Juha Hernesniemi Juha Hernesniemi Meiyun Wang Meiyun Wang Gang Liu Tianxiao Li Tianxiao Li Xingyao Bu Xingyao Bu |
| author_sort |
Jinliang Yu |
| title |
Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence |
| title_short |
Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence |
| title_full |
Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence |
| title_fullStr |
Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence |
| title_full_unstemmed |
Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence |
| title_sort |
tumor dna from tumor in situ fluid reveals mutation landscape of minimal residual disease after glioma surgery and risk of early recurrence |
| publisher |
Frontiers Media S.A. |
| series |
Frontiers in Oncology |
| issn |
2234-943X |
| publishDate |
2021-10-01 |
| description |
The recurrence of glioma is a difficult problem in clinical treatment. The molecular markers of primary tumors after resection cannot fully represent the characteristics of recurrent tumors. Here, abundant tumor DNA was detected in tumor in situ fluid (TISF). We report that TISF-derived tumor DNA (TISF-DNA) can detect genomic changes in recurrent tumors and facilitate recurrence risk analysis, providing valuable information for diagnosis and prognosis. The tumor DNA in TISF is more representative and sensitive than that in cerebrospinal fluid. It reveals the mutational landscape of minimal residual disease after glioma surgery and the risk of early recurrence, contributing to the clinical management and clinical research of glioma patients. |
| topic |
precision medicine tumor in-situ fluid circulating tumor DNA spatiotemporal heterogeneity glioma progression |
| url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.742037/full |
| work_keys_str_mv |
AT jinliangyu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT zhiyuansheng tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT zhiyuansheng tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT shuangwu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT shuangwu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT yushuaigao tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT yushuaigao tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT zhaoyueyan tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT zhaoyueyan tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT chaojiebu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT chaojiebu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT jianjungu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT jianjungu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT yagebu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT yagebu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT kaiyuandeng tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT kaiyuandeng tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT sensenxu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT sensenxu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT zhongcanchen tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT zhongcanchen tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT zhangqianqian tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT zenmarajmal tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT juhahernesniemi tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT juhahernesniemi tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT meiyunwang tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT meiyunwang tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT gangliu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT tianxiaoli tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT tianxiaoli tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT xingyaobu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence AT xingyaobu tumordnafromtumorinsitufluidrevealsmutationlandscapeofminimalresidualdiseaseaftergliomasurgeryandriskofearlyrecurrence |
| _version_ |
1716828298528423936 |
| spelling |
doaj-e15e187d8d9247cc898cae06f77afda22021-10-11T07:37:06ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-10-011110.3389/fonc.2021.742037742037Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early RecurrenceJinliang Yu0Zhiyuan Sheng1Zhiyuan Sheng2Shuang Wu3Shuang Wu4Yushuai Gao5Yushuai Gao6Zhaoyue Yan7Zhaoyue Yan8Chaojie Bu9Chaojie Bu10Jianjun Gu11Jianjun Gu12Yage Bu13Yage Bu14Kaiyuan Deng15Kaiyuan Deng16Sensen Xu17Sensen Xu18Zhongcan Chen19Zhongcan Chen20Zhang Qianqian21Zenmar Ajmal22Juha Hernesniemi23Juha Hernesniemi24Meiyun Wang25Meiyun Wang26Gang Liu27Tianxiao Li28Tianxiao Li29Xingyao Bu30Xingyao Bu31Department of Neurosurgery, Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou, ChinaDepartment of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Medical Imaging, Henan Provincial People’s Hospital, The People’s Hospital of Zhengzhou University, Zhengzhou, ChinaHenan Provincial Key Laboratory for Imaging Diagnosis and Research of Neurological Diseases, Henan Provincial People’s Hospital, The People’s Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Center for Clinical Single Cell Biomedicine, Clinical Research Center, Department of Oncology, Henan Provincial People’s Hospital, The People’s Hospital of Zhengzhou University, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, ChinaJuha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, ChinaThe recurrence of glioma is a difficult problem in clinical treatment. The molecular markers of primary tumors after resection cannot fully represent the characteristics of recurrent tumors. Here, abundant tumor DNA was detected in tumor in situ fluid (TISF). We report that TISF-derived tumor DNA (TISF-DNA) can detect genomic changes in recurrent tumors and facilitate recurrence risk analysis, providing valuable information for diagnosis and prognosis. The tumor DNA in TISF is more representative and sensitive than that in cerebrospinal fluid. It reveals the mutational landscape of minimal residual disease after glioma surgery and the risk of early recurrence, contributing to the clinical management and clinical research of glioma patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.742037/fullprecision medicinetumor in-situ fluidcirculating tumor DNAspatiotemporal heterogeneityglioma progression |